D Summerfield (March 2006 JRSM 1 ) reports that we are in a pseudo-epidemic of depression. He says that this is mainly because, with our Western classifications, we have medicalized misery and are treating it as a pathological entity with our prescriptions for antidepressants-to the benefit of the pharmaceutical industry.
Although this may be partly true, it is important to mention that our classifications change with emerging novel evidence. In fact, the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project has been set up to address nosological issues and improve the clinical utility of the concept of major depressive disorder (MDD). 2 Also, a long-term prospective, naturalistic study of depressive symptoms in MDD showed a generally fluctuating mood state with minor and subsyndromal levels alternating with the MDD syndrome in the same patients, suggestive of an illness on a continuum. 3 Furthermore, a recent well-conducted placebo-controlled study has shown fluoxetine to have efficacy in the treatment of minor depression. 4 One must not ignore the role of culture and the individual patient's narrative. However, neither can we ignore the evidence for the role of biology in depression, in particular the efficacy of antidepressants in relapse prevention. 5
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The only clear guidelines deal with acute spinal cord injury for which there is a more than 80% risk of suffering VTE in its acute stage. 3 That risk drops and becomes comparable to the normal population in 3-4 months. The reason is not completely understood, but femoral artery atrophy and reductions of venous distensibility are well documented. 4 Development of spasticity can also improve calf muscle pump. 3 These vascular changes are common to any patient with long-term immobility, so theoretically we should expect most immobile patients to behave similarly to spinal injury patients showing significant reduction of risk of VTE 4 months after the onset. To confirm or refute this hypothesis prospective studies will be needed.
Al-Razi and Islamic medicine in the 9th century
As S Tibi's article states Al-Razi was indeed an exceptional physician (April 2006 JRSM 1 ). He was a polymath, an observant clinician and a prolific writer. In one of his most noted publications he described patients with acute urethritis similar to the gonorrhoea that we see today. He was the first physician to detail full and definitive manifestations of gonorrhoea. 2 He wrote of urethral discharge and its treatment by irrigation; he was familiar with urethral stricture, and emphasized the importance of catheterization if there was a threat of retention of urine.
Ancient physicians (Hippocrates, Galen and Celsus) wrote about urethral discharge, but the overall clinical picture they presented was very different from gonorrhoea as we know it. Al-Razi was instrumental in convincing medical historians to conclude that gonorrhoea originated in the Middle Ages-a landmark in the history of venereology.
